ViiV Healthcare UK Ltd

Stockley Park West, Uxbridge, Middlesex,, UB11 1BT, UK
Telephone: +44 (0)800 221 441
Fax: +44 (0)208 990 4328
Summary of Product Characteristics last updated on the eMC: 12/12/2008
SPC Retrovir 100 mg/10ml, oral solution

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 12/12/2008 and displayed until Current
Reasons for adding or updating:
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.6 - Pregnancy and Lactation
  • Change to section 4.8 - Undesirable Effects
  • Change to section 5.2 - Pharmacokinetic Properties
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   01-Dec-2008
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company



Section 4.2 - Switch from body surface area (BSA)-based dosing (mg/m2) to bodyweight-based dosing (mg/kg), and the change from three times a day dosing to twice daily (BID) dosing

Section 4.4 - correction typographical error - superscripts

Section 4.6 - correction typographical error - superscripts

Section 4.8 - correction typographical error - superscripts

Section 5.2 - Renal impairment updated

 

Section 10 - Approval date

 

 

 


 

Updated on 15/11/2007 and displayed until 12/12/2008
Reasons for adding or updating:
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.8 - Undesirable Effects
  • Change to section 5.2 - Pharmacokinetic Properties
Date of revision of text on the SPC:   10/2007
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

Update to section 4.2 - Dosage adjustments in patients with haematological adverse reactions + Dosage in hepatic impairment

Update to section 4.4 and 4.8 - Osteonecrosis updates

Update to section 5.2 - Pharmacokinetics/distribution data in adults and children.

Updated on 15/12/2006 and displayed until 15/11/2007
Reasons for adding or updating:
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.7 - Effects on Ability to Drive and Use Machines
  • Change to section 4.8 - Undesirable Effects
  • Change to section 6. 4 - Special Precautions for Storage
  • Change to section 9 - Date of first Authorisation/renewal of the Authorisation
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   12/2006
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

For further information, please contact GlaxoSmithKline on +44 (0)800 221 441

Updated on 26/09/2005 and displayed until 15/12/2006
Reasons for adding or updating:
  • Correction of spelling/typing errors
Updated on 26/09/2005 and displayed until 26/09/2005
Reasons for adding or updating:
  • Correction of spelling/typing errors
Updated on 25/08/2005 and displayed until 26/09/2005
Reasons for adding or updating:
  • Change to section 4.4 - Special Warnings and Precautions for Use
  • Change to section 4.8 - Undesirable Effects
Updated on 20/01/2005 and displayed until 25/08/2005
Reasons for adding or updating:
  • Change to section 4.4 - Special Warnings and Precautions for Use
  • Change to section 4.8 - Undesirable Effects
Updated on 14/01/2005 and displayed until 20/01/2005
Reasons for adding or updating:
  • Change to section 5.3 - Preclinical Safety Data
Updated on 04/06/2004 and displayed until 14/01/2005
Reasons for adding or updating:
  • Correction of spelling/typing errors
Updated on 18/05/2004 and displayed until 04/06/2004
Reasons for adding or updating:
  • Change to section 4.4 - Special Warnings and Precautions for Use
Updated on 13/01/2004 and displayed until 18/05/2004
Reasons for adding or updating:
  • Change to section 1 - trade name
Updated on 13/01/2004 and displayed until 13/01/2004
Reasons for adding or updating:
  • Change to section 1 - trade name
Updated on 10/03/2003 and displayed until 13/01/2004
Reasons for adding or updating:
  • Change to section 4.4 - Special Warnings and Precautions for Use
  • Change to section 7 - Marketing Authorisation Holder
Updated on 06/02/2003 and displayed until 10/03/2003
Reasons for adding or updating:
  • Change to section 3 - pharmaceutical form
  • Change to section 4.2 - Posology and Method of Administration
  • Change to section 6. 5 - Nature and Contents of Container
Updated on 19/09/2002 and displayed until 06/02/2003
Reasons for adding or updating:
  • New SPC for eMC ie an SPC for an existing product, but one that is new for the eMC

Active Ingredients/Generics

 
   zidovudine


© 2010 Datapharm Communications Ltd

Go to www.medicines.org.uk